Different affinity of nuclear factor-kappa B proteins to DNA modified by antitumor cisplatin and its clinically ineffective trans isomer

FEBS Journal

Volumn 281, Issue 5, 2014, Pages 1393-1408

  Kasparkova, Jana ^a   Thibault, Thomas ^b   Kostrhunova, Hana ^a   Stepankova, Jana ^a   Vojtiskova, Marie ^a   Muchova, Tereza ^c   Midoux, Patrick ^b   Malinge, Jean Marc ^b   Brabec, Viktor ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

^c PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

antitumor activity; cisplatin; DNA; modified oligodeoxynucleotide decoy strategy; NF Cyrillic small letter kaB

Indexed keywords

CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLATINUM COMPLEX; PROTEIN INHIBITOR; PROTEIN P50; SYNAPTOTAGMIN I; TRANSPLATIN; UNCLASSIFIED DRUG; [4 METHYL N1 (3 PHENYLPROPYL)BENZENE 1,2 DIAMINE];

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DRUG POTENTIATION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN INTERACTION; TRANS ISOMER;

ANTITUMOR ACTIVITY; CISPLATIN; DNA; MODIFIED-OLIGODEOXYNUCLEOTIDE DECOY STRATEGY; NF-KB;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CISPLATIN; CONSENSUS SEQUENCE; DNA ADDUCTS; DNA, NEOPLASM; DRUG SYNERGISM; FEMALE; HEK293 CELLS; HUMANS; NF-KAPPA B; NUCLEIC ACID CONFORMATION; OVARIAN NEOPLASMS; PHENYLENEDIAMINES; STEREOISOMERISM;

EID: 84895491319     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12711     Document Type: Article

References (78)

1. Ghosh S, &, Karin M, (2002) Missing pieces in the NF-kappa B puzzle. Cell 109, S81-S96.
2. Pomerantz JL, &, Baltimore D, (2002) Two pathways to NF-kappa B. Mol Cell 10, 693-695.
3. Ravi R, &, Bedi A, (2004) NF-κB in cancer-a friend turned foe. Drug Resist Updates 7, 53-67.
4. Campbell KJ, &, Perkins ND, (2006) Regulation of NF-kappa B function. Transcription, pp. 165-180. Portland Press Ltd, London.
5. Hayden MS, &, Ghosh S, (2004) Signaling to NF-kappa B. Genes Dev 18, 2195-2224.
6. Verma IM, Stevenson JK, Schwarz EM, Vanantwerp D, &, Miyamoto S, (1995) Rel/NF-κ-B/I-κ-B family: intimate tales of association and dissociation. Genes Dev 9, 2723-2735.
7. Baeuerle PA, &, Henkel T, (1994) Function and activation of NF-κB in the immune system. Annu Rev Immunol 12, 141-179.
8. Thanos D, &, Maniatis T, (1995) NF-κB: A lesson in family values. Cell 80, 529-532.
9. Karin M, &, Ben-Neriah Y, (2000) Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 18, 621-663.
10. Hayden MS, &, Ghosh S, (2012) NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 26, 203-234.
11. Smale ST, (2011) Hierarchies of NF-κB target-gene regulation. Nature Immunol 12, 689-694.
12. Chen FE, Huang DB, Chen YQ, &, Ghosh G, (1998) Crystal structure of p50/p65 heterodimer of transcription factor NF-kappa B bound to DNA. Nature 391, 410-413.
13. Huang D-B, Phelps CB, Fusco AJ, &, Ghosh G, (2005) Crystal structure of a free κB DNA: insights into DNA recognition by transcription factor NF-κB. J Mol Biol 346, 147-160.
14. Schreiber J, Jenner RG, Murray HL, Gerber GK, Gifford DK, &, Young RA, (2006) Coordinated binding of NF-κB family members in the response of human cells to lipopolysaccharide. Proc Natl Acad Sci USA 103, 5899-5904.
15. Martone R, Euskirchen G, Bertone P, Hartman S, Royce TE, Luscombe NM, Rinn JL, Nelson FK, Miller P, Gerstein M, et al,. (2003) Distribution of NF-κB-binding sites across human chromosome 22. Proc Natl Acad Sci USA 100, 12247-12252.
16. Natoli G, Saccani S, Bosisio D, &, Marazzi I, (2005) Interactions of NF-κB with chromatin: the art of being at the right place at the right time. Nat Immunol 6, 439-445.
17. Wan F, Anderson DE, Barnitz RA, Snow A, Bidere N, Zheng L, Hegde V, Lam LT, Staudt LM, Levens D, et al,. (2007) Ribosomal protein S3: a KH domain subunit in NF-κB complexes that mediates selective gene regulation. Cell 131, 927-939.
18. Chen L-F, &, Greene WC, (2004) Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol 5, 392-401.
19. Wan F, &, Lenardo MJ, (2009) Specification of DNA binding activity of NF-κB proteins. Cold Spring Harb Perspect Biol 1, a000067.
20. Huxford T, Malek S, &, Ghosh G, (1999) Structure and mechanism in NF-κB/IκB signaling. Cold Spring Harb Symp Quant Biol 64, 533-540.
21. Luo J-L, Kamata H, &, Karin M, (2005) The anti-death machinery in IKK/NF-kappa B signaling. J Clin Immunol 25, 541-550.
22. Dutta J, Fan Y, Gupta N, Fan G, &, Gelinas C, (2006) Current insights into the regulation of programmed cell death by NF-kappa B. Oncogene 25, 6800-6816.
23. Nakanishi C, &, Toi M, (2005) Nuclear factor-kappa B inhibitors as sensitizers to anticancer drugs. Nature Rev Cancer 5, 297-309.
24. Baud V, &, Karin M, (2009) Is NF-kappa B a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8, 33-40.
25. Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, Van Leer D, Leister W, Austin CP, &, Xia M, (2010) Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of action. Biochem Pharmacol 79, 1272-1280.
26. Sanchez-Perez I, Benitah SA, Martinez-Gomariz M, Lacal JC, &, Perona R, (2002) Cell stress and MEKK1-mediated c-Jun activation modulate NF kappa B activity and cell viability. Mol Biol Cell 13, 2933-2945.
27. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Saito M, Kawagoe J, Takahashi K, Yada-Hashimoto N, et al,. (2004) Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279, 23477-23485.
28. Venkatraman M, Anto RJ, Nair A, Varghese M, &, Karunagaran D, (2005) Biological and chemical inhibitors of NF-κB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 44, 51-59.
29. Strozyk E, Poppelmann B, Schwarz T, &, Kulms D, (2006) Differential effects of NF-kappa B on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome. Oncogene 25, 6239-6251.
30. Dhandapani KM, Mahesh VB, &, Brann DW, (2007) Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NF kappa B transcription factors. J Neurochem 102, 522-538.
31. Solomon LA, Ali S, Banerjee S, Munkarah AR, Morris RT, &, Sarkar FH, (2008) Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB. J Ovarian Res 1, 9.
32. Chanvorachote P, Pongrakhananon V, Wannachaiyasit S, Luanpitpong S, Rojanasakul Y, &, Nimmannit U, (2009) Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cancer Invest 27, 624-635.
33. Oiso S, Ikeda R, Nakamura K, Takeda Y, Akiyama SI, &, Kariyazono H, (2012) Involvement of NF-kappa B activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells. Oncol Rep 28, 27-32.
34. Brabec V, (2002) DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog Nucleic Acid Res Mol Biol 71, 1-68.
35. Kelland L, (2007) The resurgence of platinum-based cancer chemotherapy. Nature Rev Cancer 7, 573-584.
36. Fuertes MA, Castilla J, Alonso C, &, Perez JM, (2003) Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 10, 257-266.
37. Jung Y, &, Lippard SJ, (2007) Direct cellular responses to platinum-induced DNA damage. Chem Rev 107, 1387-1407.
38. Pahl HL, (1999) Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18, 6853-6866.
39. Sathe SS, Sizemore N, Li X, Vithalani K, Commane M, Swiatkowski SM, &, Stark GR, (2004) Mutant human cells with constitutive activation of NF-κB. Proc Natl Acad Sci USA 101, 192-197.
40. Mann MJ, &, Dzau VJ, (2000) Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 106, 1071-1075.
41. Osako MK, Tomita N, Nakagami H, Kunugiza Y, Yoshino M, Yuyama K, Tomita T, Yoshikawa H, Ogihara T, &, Morishita R, (2007) Increase in nuclease resistance and incorporation of NF-κB decoy oligodeoxynucleotides by modification of the 3′-terminus. J Gene Med 9, 812-819.
42. Sun X, Zhang J, Wang L, &, Tian Z, (2008) Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 262, 201-213.
43. Gao HH, Xiao JN, Sun Q, Lin HX, Bai YL, Yang L, Yang BF, Wang HZ, &, Wang ZG, (2006) A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anticancer effects. Mol Pharmacol 70, 1621-1629.
44. Kisova A, Zerzankova L, Habtemariam A, Sadler PJ, Brabec V, &, Kasparkova J, (2011) Differences in the cellular response and signaling pathways between cisplatin and monodentate organometallic Ru(II) antitumor complexes containing a terphenyl ligand. Mol Pharmaceutics 8, 949-957.
45. Yu L, &, Wang Z, (2004) Difference in expression of Bcl-2 and Bcl-xl genes in cisplatin-sensitive and cisplatin-resistant human in ovarian cancer cell lines. J Huazhong Univ Sci Technol Med Sci 24, 151-153.
46. Shin HM, Kim MH, Kim BH, Jung SH, Kim YS, Park HJ, Hong JT, Kyung RM, &, Kim Y, (2004) Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappa B without affecting I kappa B degradation. FEBS Lett 571, 50-54.
47. Kumar A, Negi G, &, Sharma SS, (2011) JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obesity Metab 13, 750-758.
48. Chou T-C, &, Talalay P, (1983) Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4, 450-454.
49. Chou TC, &, Talalay P, (1984) Quantitative-analysis of dose-effect relationships-the combined effects of multiple-drugs or enzyme-inhibitors. Adv Enzyme Regul 22, 27-55.
50. Muller CW, Rey FA, Sodeoka M, Verdine GL, &, Harrison SC, (1995) Structure of the NF-κB p50 homodimer bound to DNA. Nature 373, 311-317.
51. Ghosh G, Vanduyne G, Ghosh S, &, Sigler PB, (1995) Structure of NF-κB P50 homodimer bound to a κB site. Nature 373, 303-310.
52. Muller CW, Rey FA, &, Harrison SC, (1996) Comparison of two different DNA-binding modes of the NF-kappa B p50 homodimer. Nature Struct Biol 3, 224-227.
53. Cramer P, Larson CJ, Verdine GL, &, Muller CW, (1997) Structure of the human NF-kappa B p52 homodimer-DNA complex at 2.1 angstrom resolution. EMBO J 16, 7078-7090.
54. Yang DZ, van Boom SSGE, Reedijk J, van Boom JH, &, Wang AHJ, (1995) Structure and isomerization of an intrastrand cisplatin-cross-linked octamer DNA duplex by NMR analysis. Biochemistry 34, 12912-12920.
55. Gelasco A, &, Lippard SJ, (1998) NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) adduct d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry 37, 9230-9239.
56. 3 by an iminoether in transplatin makes an antitumor drug from an inactive compound. Mol Pharmacol 58, 1525-1535.
57. Leng M, Schwartz A, &, Giraud-Panis MJ, (2000) Transplatin-modified oligonucleotides as potential antitumor drugs. In Platinum- Based Drugs in Cancer Therapy (, Kelland LR, &, Farrell NP, eds), pp. 63-85. Humana Press Inc, Totowa/NJ.
58. Brabec V, Sip M, &, Leng M, (1993) DNA conformational distortion produced by site-specific interstrand cross-link of trans- diamminedichloroplatinum(II). Biochemistry 32, 11676-11681.
59. Brabec V, Reedijk J, &, Leng M, (1992) Sequence-dependent distortions induced in DNA by monofunctional platinum(II) binding. Biochemistry 31, 12397-12402.
60. Keck MV, &, Lippard SJ, (1992) Unwinding of supercoiled DNA by platinum ethidium and related complexes. J Am Chem Soc 114, 3386-3390.
61. Brabec V, &, Leng M, (1993) DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc Natl Acad Sci USA 90, 5345-5349.
62. Brabec V, (2000) Chemistry and structural biology of 1,2-interstrand adducts of cisplatin. In Platinum-based Drugs in Cancer Therapy (, Kelland LR, &, Farrell NP, eds), pp. 37-61. Humana Press Inc, Totowa/NJ.
63. Kasparkova J, Pospisilova S, &, Brabec V, (2001) Different recognition of DNA modified by antitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53. J Biol Chem 276, 16064-16069.
64. Kasparkova J, Fojta M, Farrell N, &, Brabec V, (2004) Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin. Nucleic Acids Res 32, 5546-5552.
65. Wang D, &, Lippard SJ, (2005) Cellular processing of platinum anticancer drugs. Nature Rev Drug Discov 4, 307-320.
66. Todd RC, &, Lippard SJ, (2009) Inhibition of transcription by platinum antitumor compounds. Metallomics 1, 280-291.
67. Zhai XQ, Beckmann H, Jantzen HM, &, Essigmann JM, (1998) Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. Biochemistry 37, 16307-16315.
68. Kartalou M, &, Essigmann JM, (2001) Recognition of cisplatin adducts by cellular proteins. Mutation Res 478, 1-21.
69. Damsma GE, Alt A, Brueckner F, Carell T, &, Cramer P, (2007) Mechanism of transcriptional stalling at cisplatin-damaged DNA. Nature Struct Mol Biol 14, 1127-1133.
70. Danford AJ, Wang D, Wang Q, Tullius TD, &, Lippard SJ, (2005) Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes. Proc Natl Acad Sci USA 102, 12311-12316.
71. Ober M, &, Lippard SJ, (2007) Cisplatin damage overrides the predefined rotational setting of positioned nucleosomes. J Am Chem Soc 129, 6278-6286.
72. Ober M, &, Lippard SJ, (2008) A 1,2-d(GpG) cisplatin intrastrand cross-link influences the rotational and translational setting of DNA in nucleosomes. J Am Chem Soc 130, 2851-2861.
73. Grivennikov SI, &, Karin M, (2010) Dangerous liaisons: STAT3 and NF-kappa B collaboration and crosstalk in cancer. Cyt Growth Factor Rev 21, 11-19.
74. Kasparkova J, Farrell N, &, Brabec V, (2000) Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes. J Biol Chem 275, 15789-15798.
75. 2]. Eur J Biochem 202, 975-980.
76. Taylor BS, de Vera ME, Ganster RW, Wang Q, Shapiro RA, Morris SM, Billiar TR, &, Geller DA, (1998) Multiple NF-κB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem 273, 15148-15156.
77. Fujita T, Nolan GP, Ghosh S, &, Baltimore D, (1992) Independent modes of transcriptional activation by the p50-subunit and p65-subunit of NF-kappa-B. Genes Dev 6, 775-787.
78. De Wet JR, Wood KV, Deluca M, Helinski DR, &, Subramani S, (1987) Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 7, 725-737.